Pomegra
Moderna Stock Jumps 9% After Q3 Earnings Beat
Why is Moderna stock up today?
Moderna (MRNA) stock rose about 9% to $263.11 on Friday after the vaccine maker beat third-quarter estimates and raised its 2026 revenue growth outlook to 15%–25%, from up to 10% before.
Key numbers
| Q3 2026 revenue | $1.31B+29% YoY |
|---|---|
| Q3 earnings per share | $0.38vs. expected loss |
| 2026 revenue growth outlook | 15%–25%was up to 10% |
| Expected year-end cash | $8.1B–$8.3Bwas $4.7B–$5.2B |
| Stock price, midday (per [4]) | $263.11+9.0% on the day |
| Stock, year to date | +762%more than +700% per CNBC |
What happened
Moderna (MRNA) stock rose about 9% to $263.11 on Friday after the vaccine maker beat third-quarter estimates and raised its 2026 revenue growth outlook to 15%–25%, from up to 10% before. Quarterly sales were $1.31 billion, up 29% from a year ago, versus about $890 million analysts expected. It also earned $0.38 per share when analysts expected a loss. Management said some of the strength came from the timing of shipments. Moderna also lifted its expected year-end cash to $8.1 billion–$8.3 billion.
Why it matters
Moderna's higher forecast signals that its vaccine sales are growing, helped by new products and long-term deals with foreign governments. The company now expects to end the year with much more cash than it planned, which gives it more room to fund new medicines such as its melanoma cancer vaccine. The stock is already up more than 700% this year, so expectations are high. Part of the quarter's strength may not repeat.
Who this affects
- MarketbullishMedium impact
- Vaccine-stock investors gain as Moderna beats estimates.
- CompanybullishHigh impact
- Shareholders gain from higher sales outlook and more cash.
- CompetitorsmixedLow impact
- Pfizer slipped 2%; BioNTech rose 1.4% in same session.
- IndustrymixedMedium impact
- Covid vaccine sales abroad helped; lasting demand is uncertain.
Moderna vs Pfizer, BioNTech
How we got here
Moderna and Merck report positive Phase 3 melanoma cancer vaccine (intismeran) data
Moderna reports Q3 revenue of $1.31B and raises 2026 growth outlook to 15%–25%
Shares jump about 9% midday while Pfizer slips about 2%
What to watch
- Whether Q3 shipment-timing gains reverse in fourth-quarter salesQ4 2026
- Effect of $950M litigation settlement and failed norovirus trial on spendingQ4 2026
- Whether full-year revenue lands inside the new 15%–25% growth rangeQ1 2027
Educational content only. Not investment advice.
More briefsAll briefs →
Lam Research Stock Jumps 10% After $25B Buyback
Lam Research (LRCX) rebounded as the chip index recovered from a 12% rout driven by AI-rule worries.
Fed Rate Hike Odds Jump Above 75% After Strong Jobs Report
US employers added 165,000 jobs in October and unemployment fell to 4.1%, well ahead of the 65,000 forecast.
S&P 500 Rises 0.9% as Chip Stocks Rebound
S&P 500 (^GSPC) rose as the Nasdaq gained 1.6% and the VIX fell, with Nvidia and Micron bouncing back